Home Applications 761125 Application 761125
Type BLA
Sponsor NOVARTIS PHARMS CORP Purple Book Biologic Products# BLA, Proprietary name, Proper name table BLA Proprietary name Proper name License type Status Latest source 761125 Beovu brolucizumab-dbll 351(a) Rx 2026-06-01
Application Products# Product, Drug, Ingredient table Product Drug Ingredient Form Strength Reference drug Reference standard 001 BEOVU brolucizumab-dbll INJECTABLE; INTRAVITREAL 6MG/0.05ML No No
openFDA label cross-check# OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
Matched openFDA labels page 1 of 1 · 1 matching rows.
Brand, Generic, Manufacturer table Brand Generic Manufacturer SPL set ID Effective date Available safety fields Join BEOVU BROLUCIZUMAB Novartis Pharmaceuticals Corporation 5d1dc1fa-a2d3-46ed-9e9a-c1a036590d3d 2025-11-03 Warnings, Adverse reactions Exact identifier application number: BLA761125 ndc (product): 0078-0827
NDC Listings For This Application# NDC listings for this application page 1 of 1 · 9 matching rows.
NDC, Name, Nonproprietary name table NDC Name Nonproprietary name Labeler Marketing category Status 0078-0827 BEOVU brolucizumab Novartis Pharmaceuticals Corporation BLA Current 0078-0827 BEOVU brolucizumab Novartis Pharmaceuticals Corporation BLA Current 0078-0827 BEOVU brolucizumab Novartis Pharmaceuticals Corporation BLA Current 0078-0827 BEOVU brolucizumab Novartis Pharmaceuticals Corporation BLA Current 0078-0827 BEOVU brolucizumab Novartis Pharmaceuticals Corporation BLA Current 0078-0827 BEOVU brolucizumab Novartis Pharmaceuticals Corporation BLA Current 0078-0827 BEOVU brolucizumab Novartis Pharmaceuticals Corporation BLA Current 0078-0827 BEOVU brolucizumab Novartis Pharmaceuticals Corporation BLA Current 0078-0827 BEOVU brolucizumab Novartis Pharmaceuticals Corporation BLA Current